Abstract: Compounds exhibiting antiviral activity and/or inhibition of viral replication against viruses, particularly those belonging to the picornavirus-like supercluster, including coronavirus having a formula: (I) where X comprises a cyclic moiety, R2 is a branched or unbranched alkyl, cycloalkyl, aryl, arylalkyl, alkenyl, alkynyl, amino acid side chain, bicyclic or tricyclic side chain, combinations, and substituted forms thereof, and Z is selected from the group consisting of C1-C6 hydroxyalkyl, aldehydes, alpha-ketoamides, and bisulfite salts, and in particular —CH2OH, —CHO, —CH(0H)S03?Na+, and -[0(C=0)Rw]S03?Na+.

Abstract: Compounds and treatment methods with compounds exhibiting antiviral activity and/or inhibition of viral replication against viruses, particularly those belonging to the picornavirus-like supercluster, including coronavirus having a formula: or a prodrug or pharmaceutically-acceptable salt thereof, where: each X comprises at least one cyclic moiety directly attached to the oxygen or connected via an alkyl linkage, where at least one of the linkage and/or the X moiety comprises a deuterium substitution; and Z is selected from the group consisting of aldehydes and bisulfite salts, or the ester or carbamate prodrugs thereof.

Abstract: Disclosed herein are protease transition state inhibitor/analogue prodrug compounds selected from the group consisting of esters, carbamates, ester phosphates, and pharmaceutically acceptable salts thereof. Compositions containing such prodrugs are also disclosed, along with methods of using such compounds therapeutically or prophylactically against calicivirus, picornavirus, and/or coronavirus infection, as well as other conditions, such as malaria, cancer, stroke, heart attack, neural degeneration, cataracts, and glaucoma through inhibition of the variety of proteases associated with progression of such conditions.

Abstract: Antiviral protease inhibitors are disclosed, along with related antiviral dipeptidyl compounds, macrocyclic derivatives thereof and methods of using the same to treat or prevent viral infection and disease from coronaviruses, caliciviruses, and picornaviruses.

Abstract: Antiviral protease inhibitors are disclosed, along with related antiviral dipeptidyl compounds, macrocyclic derivatives thereof and methods of using the same to treat or prevent viral infection and disease from coronaviruses, caliciviruses, and picornaviruses.

Abstract: Disclosed herein are protease transition state inhibitor/analogue prodrug compounds selected from the group consisting of esters, carbamates, ester phosphates, and pharmaceutically acceptable salts thereof. Compositions containing such prodrugs are also disclosed, along with methods of using such compounds therapeutically or prophylactically against calicivirus, picornavirus, and/or coronavirus infection, as well as other conditions, such as malaria, cancer, stroke, heart attack, neural degeneration, cataracts, and glaucoma through inhibition of the variety of proteases associated with progression of such conditions.

Abstract: Isolated porcine epidemic diarrhea virus (PEDV) deposited under ATCC Accession No. PTA-121847, and attenuated strains generated by serial passage in culture of the deposited strain. Immunogenic compositions for reducing the incidence or severity of clinical symptoms from PEDV infection, and methods of making and using the same.

Abstract: Isolated porcine epidemic diarrhea virus (PEDV) deposited under ATCC Accession No. PTA-121847, and attenuated strains generated by serial passage in culture of the deposited strain. Immunogenic compositions for reducing the incidence or severity of clinical symptoms from PEDV infection, and methods of making and using the same.

Abstract: Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl ?-ketoamides, peptidyl bisulfate salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

Abstract: Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

Abstract: Antiviral protease inhibitors, including peptidyl aldehydes, peptidyl ?-ketoamides, peptidyl bisulfite salts, and peptidyl heterocycles, are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus.

Abstract: The present invention provides the genes encoding the following BRV proteins: for group A, the VP4 and VP7 proteins of the Indiana (IND) strain, and the VP7 protein of the 2292B strain; for group B, the VP7 protein of the WD653 strain; for group C, the VP4 and VP7 proteins of the Shintoku strain. The genes are useful for producing nucleic acid probes which are complementary to the VP7 and VP4 genes. Such probes are useful for detecting the presence of group A,B, and C BRV in fecal samples from diarrheic calves and for determining the serotype of the BRV field isolates. The genes are also useful for producing partial length nucleic acid probes which are complementary to hypervariable regions of the VP4 and VP7 genes. The present invention also relates to partially purified VP2, VP4, VP6 and VP7 proteins of the IND strain and VP4 and VP7 of the 2292B strain, the partially purified VP7 protein of the WD653 strain, and partially purified VP2, VP4 and VP7 proteins of the Shintoku strain.

Abstract: The present invention provides the genes encoding the following BRV proteins: for group A, the VP4 and VP7 proteins of the Indiana (IND) strain, and the VP7 protein of the 2292B strain; for group B, the VP7 protein of the WD653 strain; for group C, the VP4 and VP7 proteins of the Shintoku strain. The genes are useful for producing nucleic acid probes which are complementary to the VP7 and VP4 genes. Such probes are useful for detecting the presence of group A,B, and C BRV in fecal samples from diarrheic calves and for determining the serotype of the BRV field isolates. The genes are also useful for producing partial length nucleic acid probes which are complementary to hypervariable regions of the VP4 and VP7 genes.The present invention also relates to partially purified VP2, VP4, VP6 and VP7 proteins of the IND strain and VP4 and VP7 of the 2292B strain, the partially purified VP7 protein of the WD653 strain, and partially purified VP2, VP4 and VP7 proteins of the Shintoku strain.